To date, an adequate and timely assessment of the number of cases is the basis of effective measures aimed at preventing the spread of COVID-19 infection. Real-time reverse transcription polymerase chain reaction (RT-PCR) remains the gold standard for confirming COVID-19.The purpose of the work: to analyze the experience of the city virological center of the S.P. Botkin Clinical Infectious Diseases Hospital (Botkin Hospital) for the examination for the presence of SARS-CoV-2 coronavirus by PCR in the period from 2020 to 2022.Materials and methods. The systematization of PCR studies on COVID-19 for the period 2020-2022 was carried out. A total of 221,901 people were examined, positive results were obtained in 55,372 (24.95%). Among the contingents of the examined patients, patients who underwent inpatient treatment at the Botkin Hospital.Conclusions. This study analyzed the possible causes of false-positive and false-negative PCR results. The correlation of the number of positive results with the dynamics of detection of new cases of COVID-19 in St. Petersburg during the 2020-2022 pandemic is shown. It has been established that the proportion of patients examined more than 3 times during the period of hospitalization remains significant. This fact requires the closest attention, given the high cost and laboriousness of PCR studies.
Currently, despite the wide variety of methods and tests for screening blood serum for antibodies to HCV, there are no reliable criteria that guarantee a reliable result. To date, the interpretation of the results of anti-HCV detection in samples with low CP values (low optical density in ELISA) remains one of the major tasks of laboratory diagnostics. Continuous improvement of analytical sensitivity and specificity of laboratory tests remains one of the priority tasks for manufacturers of modern test systems. The purpose of this article was to assess the specificity and sensitivity of the new Hepatitis ELISA-anti-HCV test system produced by Alkor Bio when compared with test systems from other manufacturers in settings with sera from real patients and in a series of control seroconversion panels. The article is intended for doctors of clinical laboratory diagnostics, epidemiologists, virologists, infectious disease specialists, students of medical and biological universities.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.